Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To report the toxicity and preliminary clinical outcomes of a prospective trial evaluating 19-Gy, single-fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int. J. Radiat. Oncol. Biol. Phys.

Title: International journal of radiation oncology, biology, physics

Publisher: Elsevier BV

ISSN (Electronic): 1879-355X

ISSN (Print): 0360-3016

Publication date (Electronic): Jan 01 2017

Volume: 97

Issue: 1

Affiliations

[1 ] Oakland University William Beaumont School of Medicine, Royal Oak, Michigan. Electronic address: dkrauss@beaumont.edu.

[2 ] Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.

[3 ] 21st Century Oncology, Farmington Hills, Michigan.

Article

Publisher Item ID: S0360-3016(16)33096-6

DOI: 10.1016/j.ijrobp.2016.08.011

PubMed ID: 27979460

SO-VID: b2d9d631-a284-481c-a651-bd86760077f3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 17

See all cited by

Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.

Read this article at

Nanopublications (single, attributable and machine-readable assertions in scientific literature)

Journal

Affiliations

Article

History

Comment on this article